Notably, the effectiveness of EGFR-CD3 bsAb has been shown in preclinical studies, including those on glioblastoma, pancreatic, and colon cancers 74-77; for these tumor models, our findings (Figure 5G) suggest a synergistic antitumor effect when bsAb are combined with RNase1 treatment. Here, RNASE1 is linked to malignant colon neoplasm.